Seagen, Inc.
Bothell
WA
United States
874 articles about Seagen, Inc.
-
Seagen Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer
9/19/2022
Seagen Announces TUKYSA ® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer.
-
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer
9/12/2022
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV ® (enfortumab vedotin-ejfv) with KEYTRUDA ® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer.
-
Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer
9/12/2022
Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), Seagen Inc. (Nasdaq:SGEN) and Merck (NYSE: MRK) today announced results from the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869) Cohort K investigating PADCEV® (enfortumab vedotin-ejfv) in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and PADCEV alone as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer.
-
Seagen to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
9/7/2022
Seagen Inc. announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022 at 12:55 p.m. Eastern Time.
-
Seagen to Highlight Research in Urothelial and Colorectal Cancers at 2022 European Society for Medical Oncology (ESMO) Congress
9/7/2022
Seagen Inc. (Nasdaq:SGEN) today announced upcoming presentations of new data from its clinical development programs at the European Society for Medical Oncology (ESMO) Congress 2022, to be held September 9-13 in Paris, France.
-
The BioForest region is growing up. With a focus on cell and gene therapy, a wealth of talent and proximity to high tech, it is quickly becoming one of biotech's most exciting hotbeds.
-
Merck's bid to buy the cancer-focused Seagen has hit a roadblock after the two companies failed to agree on a price, according to a Bloomberg report.
-
As the biotech world awaits the announcement of Merck’s anticipated buyout of Seagen, an arbitrator came down on the side of Daiichi Sankyo in a patent battle against the Seattle-based biotech.
-
InMed updated its INM-755 for patients with epidermolysis bullosa, Seagen and Astellas announced positive topline results for Padcev with Merck’s Keytruda, and more.
-
Seagen Reports Second Quarter 2022 Financial Results
7/28/2022
Seagen Inc. reported financial results for the second quarter ended June 30, 2022.
-
Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
7/26/2022
Seagen Inc. and Astellas Pharma Inc. announced positive topline results from the phase 1b/2 EV-103 clinical trial Cohort K evaluating PADCEV® in combination with Merck’s anti-PD-1 therapy KEYTRUDA® as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer who are ineligible to receive cisplatin-based chemotherapy.
-
Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
7/26/2022
Astellas Pharma Inc. and Seagen Inc. announced positive topline results from the phase 1b/2 EV-103 clinical trial Cohort K evaluating PADCEV® in combination with Merck's anti-PD-1 therapy KEYTRUDA® as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer who are ineligible to receive cisplatin-based chemotherapy.
-
BridgeBio announces positive Phase II trial results for achondroplasia, Astellas-Seagen announces promising outcomes from Padcev Plus Keytruda Trial and Kelun-Biotech's exclusive MSD deal.
-
The delay is due, in part, to some internal Seagen actions, including a data readout for its bladder cancer drug Padcev, as well as a legal matter between Seagen and Daiichi Sankyo.
-
Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2022 Financial Results on July 28, 2022
7/8/2022
Seagen Inc. (Nasdaq: SGEN) today announced that it will report its second quarter 2022 financial results on Thursday, July 28, 2022 after the close of U.S. financial markets.
-
Merck is in late-stage discussions to acquire Seagen for about $40 billion according to a Wall Street Journal report.
-
Seagen announced positive data from its Phase II trial in colorectal cancer, and the FDA provided positive feedback supporting a Phase IIIb trial for ANeuroTech’s MDD drug.
-
Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meaningful Antitumor Activity of TUKYSA® (tucatinib) in Combination with Trastuzumab in Previously Treated HER2-Positive Metastatic Colorectal Cancer
7/2/2022
Seagen Inc. announced full results from the pivotal phase 2 MOUNTAINEER trial, which showed TUKYSA® in combination with trastuzumab was well-tolerated with durable responses in patients with previously treated HER2-positive metastatic colorectal cancer.
-
Talks between Merck and Seagen are heating up as the former looks to buy the latter, according to a report published by The Wall Street Journal.
-
Pharmaceutical giant Merck is exploring a possible purchase of biotech company Seagen, according to The Wall Street Journal.